Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | 3004333 | PO / MO |
The patient took two doses of Vivotif in a row; Case reference number US-BN-2025-001188 is a spontaneous case initially received from a nurse via Communication (reference number: USBAV25-1688) on 10-Jul-2025 and concerns a 58-year-old, female patient. The patient's medical history included insomnia. The patient's concomitant medication details were not provided. On 09-Jul-2025, the patient took the first dose of Vivotif (batch number: 3004333) orally, at an unknown dose, for travel. On 10-Jul-2025, one day after the vaccination with the first dose, the patient took the second dose of Vivotif (batch number: 3004333) orally, at an unknown dose (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A 58-year-old female patient took the second dose of Vivotif for travel, one day after the vaccination with the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history included insomnia, and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 58-year-old female patient took the second dose of Vivotif for travel, one day after the vaccination with the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history included insomnia, and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Medical History/Concurrent Conditions: Insomnia; Comments: NONE